BackLiminal Biosciences Overview

Liminal Biosciences Accounts Payable

Liminal Biosciences's accounts payable is $0.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$0.00

Peer trimmed avg / median

Loading

Liminal Biosciences Accounts Payable History

Loading

Liminal Biosciences vs. peers: Accounts Payable Comparison

Loading

Liminal Biosciences Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Liminal Biosciences (LMNL) FAQ

Liminal Biosciences (LMNL) currently reports a accounts payable of $0 as of June 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Liminal Biosciences's accounts payable history and peer comparisons.

Liminal Biosciences's accounts payable changed from $0 to $0 (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Liminal Biosciences reported $0 in accounts payable as of June 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Liminal Biosciences, and consider following LMNL for alerts when major investors trade the stock.

Liminal Biosciences is classified in the Healthcare sector. On accounts payable, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LMNL with unrelated industries.